U.K.' s NICE To Evaluate Efficacy of Bristol's Taxol In Ovarian Cancer
Executive Summary
The U.K.' s National Institute of Clinical Excellence plans an assessment of ovarian cancer therapies with Bristol-Myers Squibb's Taxol (paclitaxel) as one of its first priorities, the Department of Health announced Aug. 6.
You may also be interested in...
Glaxo Decides Not To Pursue U.K. Flu Awareness Campaign For Relenza
The potential negative impact on the U.K.' s National Health Service drug budget may be one factor behind Glaxo Wellcome's decision not to launch a flu awareness campaign for its neuraminidase inhibitor Relenza (zanamivir) in the U.K.
Glaxo Decides Not To Pursue U.K. Flu Awareness Campaign For Relenza
The potential negative impact on the U.K.' s National Health Service drug budget may be one factor behind Glaxo Wellcome's decision not to launch a flu awareness campaign for its neuraminidase inhibitor Relenza (zanamivir) in the U.K.
U.K. Regulators To Consider FDA-Style Transparency
The U.K.' s Medicines Control Agency will consider the adoption of FDA-style transparency to communicate information about its activities more effectively, according to a five-year review of the agency conducted by the U.K. Department of Health.